Current role
Nicholas A. LaBella
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Nicholas A. LaBella
ZyVersa Therapeutics, Inc. reported in an 8-K filed August 18, 2023 that Nicholas A. LaBella retired as Chief Scientific Officer and Senior Vice President of Research and Development, effective August 18, 2023. ZyVersa Therapeutics, Inc. reported in an 8-K filed December 13, 2022 that Nicholas A. LaBella was appointed Chief Scientific Officer. ZyVersa Therapeutics, Inc. reported in an 8-K filed December 13, 2022 that Nicholas A. LaBella was appointed Chief Scientific Officer, effective December 12, 2022.
“On August 7, 2023, Nicholas A. LaBella, Jr., Chief Scientific Officer and Senior Vice President of Research and Development at ZyVersa Therapeutics, Inc. (the “Company”) notified the Company of his planned retirement from the Company effective August 18, 2023.”
“Nicholas A. LaBella was appointed Chief Scientific Officer”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2022-12-12–present
-
2022-12-12–2023-08-18
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at ZyVersa Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Stephen C. Glover CEO, Board Member
- Peter Wolfe CFO
- Daniel J. O'Connor Board Member
- Gregory Freitag Board Member
- James Sapirstein Board Member
- Katrin Rupalla Board Member
- Min Chul Park, Ph.D. Board Member
- Min-Chul Park Board Member
- Rob G. Finizio Board Member
- Robert Finizio Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.